PROGRAM BOOK
Explore the Program Book and discover the full scientific program, sessions, speakers, and key Conference information, all in one place to help you plan your time in Seoul.
ONSITE INFORMATION
Get ready for WCLC 2026 with essential onsite information covering the venue, opening hours, mobile app, and practical details to help you navigate the Conference.
Presidential Symposia
Discover the latest research from SWOG S1827 MAVERICK, TAISHAN-302, ARTEMIS-008, EVOKE-03, ADAURA, PAPILLON, REZILIENT 3, ARROS-1, and DESTINY.
WCLC NEWS
-
Overall Survival Benefit Seen in Interim Analysis of ARTEMIS-008 Signals Rapidly Expanding Landscape of ADC-Based Therapies in Small Cell Lung Cancer
Prof. Jie Wang, MD, said risvutatug rezetecan, a B7-H3-directed antibody-drug conjugate, demonstrated an overall survival benefit compared with topotecan in patients with relapsed SCLC.
-
Adjuvant Osimertinib Demonstrates Sustained OS Benefit in Resected EGFR-Mutated NSCLC
Presented by Roy S. Herbst, MD, PhD, an exploratory analysis of the global phase III ADAURA trial reveals sustained overall survival benefit—over the longest follow-up to date—in resected EGFR-mutated NSCLC.
-
Overall Survival Benefit Not Seen with Amivantamab-Chemotherapy in Phase III PAPILLION Trial
Presenter Chul Kim, MD, MPH, said crossover from the chemotherapy arm may have contributed to the overall survival improvement failing to reach statistical significance.
-
Four Multidisciplinary Teams to Face Off During the Closing Lunch and Game Show
As WCLC 2026 comes to a close, join Master of Ceremonies Dr. Corey J. Langer to see who will emerge victorious in this quiz-style competition.
-
An Essential Component: Rethinking the Role of Exercise in Lung Cancer Care
Dr. Morten Quist discusses the increasing evidence supporting exercise for patients with lung cancer and emphasizes the need to incorporate evidence-based physical activity into routine care.
-
Anti-B7-H3 ADC Tam-Peli Tops Topotecan in Phase III Study
Interim data from the TAISHAN-302 trial, presented by Prof. Li Zhang, Sun Yat-sen University Cancer Center, revealed improvements in ORR, OS, and PFS with tambotatug pelitecan versus topotecan, the standard second-line treatment for patients with relapsed SCLC.
SEPTEMBER 12 - 15, 2026
JOIN US FOR WCLC 2026
WCLC 2026 brings together the world’s leading lung cancer researchers, clinicians, nurses, and advocates for a transformative week of learning and collaboration. With 7,000+ international attendees, 130+ sessions and workshops, and 2,300+ abstracts, WCLC 2026 is your opportunity to connect with global experts, gain cutting-edge insights, and advance the field of thoracic oncology.
Meet the opening Plenary Speakers
Mark Your Calendars
IMPORTANT DATES
September 12 - 15, 2026
Conference Dates
August 19, 2026
Full Abstract Release
September 3, 2026
Launch of the Mobile App
WHAT TO EXPECT
E-Posters
Be the first to receive important updates, deadlines, and announcements for WCLC 2026 — straight to your inbox.
"
WCLC is always an impressive conference and I always find exciting information that I can use to develop new treatment regiments for my patients.
Yanyan Wang
IASLC Member – China
"
WCLC is always a highlight of my year! As a pathologist, it’s fabulous to attend a multidisciplinary conference with people sharing ideas and giving insights from every perspective.
Keith Kerr
IASLC Member – United Kingdom
"
The WCLC atmosphere is amazing! As a medical student, the opportunity to hear from and talk to the biggest doctors in the industry is an experience of a lifetime.
Sanad Alhushki
Medical Student – Jordan